Dynamics of osteopontin levels during therapy with candesartan in patients on program hemodialysis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. Evaluation of the features of plasma osteopontin levels, arterial hypertension, cardiovascular remodeling against the background of therapy with candesartan, and identifying the relationships between these parameters in patients with chronic kidney disease who receive program hemodialysis. Methods. Patients underwent 24-hour blood pressure monitoring, echocardiography, carotid Doppler sonography, determination of plasma osteopontin levels using enzyme immunoassay during 12-week treatment with candesartan. Results. The therapy significantly reduced mean systolic blood pressure and pulse pressure, a decreased the relative left ventricular wall thickness, decreased the left ventricular mass index, and reduced plasma osteopontin levels. At the same time, positive correlations between indicators of cardiovascular remodeling, blood pressure and osteopontin levels was found. Conclusion. Application of candesartan cilexetil in the population of hemodialysis patients contributes to the regression of left ventricular hypertrophy and indicators of vascular remodeling, and has antihypertensive effect. Osteopontin can be considered as a marker of cardiovascular remodeling in a cohort of patients receiving renal replacement therapy by program hemodialysis.

Full Text

Restricted Access

About the authors

E. G Ovskaya

Email: DOCALEN@RAMBLER.RU

References

  1. Визир В.А., Березин А.Е. Остеопонтин как новый биологический маркер кардиоваскулярного ремоделирования // Кровообіг та гемостаз. - 2010. - № ½. - С. 42-47.
  2. Гарсиа-Донаире Ж.А. Кардио-васкулярно-ренальные связи в кардиоренальном континууме // Нефрология. - 2013. - № 17(1). - С. 11-19.
  3. Ртищева О.В., Калев О.Ф. Особенности структурного ремоделирования миокарда у больных артериальной гипертензией, находящихся на гемодиализе // Клиническая нефрология. - 2011. - № 2. - С. 35-39.
  4. Barra S., Vitagliano A., Cuomo V. [et al]. Vascular and metabolic effects of angiotensin II receptor blockers // Expert Opin. Pharmacother. - 2009. - Vol. 10(2). - P. 173-189.
  5. Cecilia M. Giachelli. The emerging role of phosphate in vascular calcification // Ridney International. - 2009. - Vol. 75. - P. 890-897.
  6. Denhardt D.T., Noda M., O’Regan A.W. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival // J Clin Invest. - 2007. - Vol. 107. - P. 1055-1061.
  7. Devereux R.B., Alonso D. R., Lutas E. M. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings // Am J Cardiol. - 1986. - Vol. 57. - P. 450-458.
  8. ESH/ESC Guidelines for the management of arterial hypertension 2013.
  9. Friedman O., McAlister F.A., Yun L. [et al]. Hypertension Education Program Outcomes Research Taskforce. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario // Am. J. Med. - 2010. - Vol. 123 (2). - P. 173-181.
  10. Giachelli C.M., Speer M.Y., Li X. [et al]. Regulation of vascular calcification: Roles of phosphate and osteopontin // Circ Res. - 2005. - Vol. 96. - P. 717-722.
  11. Glynn L.G., Reddan D., Newell J. [et al]. Cronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland communiti-based cohort study // Nephrol Dial Transplant. - 2007. - Vol. 22(9). - P. 2586-2594.
  12. Grau J.B., Poggio P., Sainger R. Osteopontin Levels for the Identification of Asymptomatic Patients with Calcific Aortic Valve Disease. Annals of Thoracic Surgery // Annals of Thoracic Surgery. - 2012. - Vol. 93(1). - P. 79-86.
  13. Hatanaka Y., Umekawa T., Iguchi M. et al. Evaluation of the crystal inhibitory effect of angiotensin II type I receptor blocker in etylene glycol treated rat kidney // Nippon Hinyokika Gakkai Zasshi. - 2005. - Vol. 96(4). - P. 487-494.
  14. Heerspink H.J., Ninomiya T., Zoungas S. [et al]. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials // Lancet. - 2009. - Vol. 373. - P. 1009-1015.
  15. Jula K. Inrig. Antihypertensive Agents in Hemodialysis Patients: A Current Perspective // Semin Dial. - 2010. - Vol. 23(3). - P. 290-297.
  16. Kurata M., Okura T., Irita J. [et al]. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension // J Hum Hypertens. - 2011. - Vol. 25(5). - P. 334-339.
  17. Lorenzen J.M., Neunhöffer H., David S. [et al]. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-results from the EUTOPIA trial // Atherosclerosis. - 2010. - Vol. 209(1). - P. 184-188.
  18. Di Lullo L., Floccari F., Santoboni A. [et al]. Progression of cardiac valve calcification and decline of renal function in CKD patients // J Nephrol. - 2013. - Vol. 26(4). - P. 739-744.
  19. Nakayama H., Nagai H., Matsumoto K. [et al]. Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese population // Hypertens Res. - 2011. - Vol. 34(10). - P. 1141-1146.
  20. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis // Am J Kidney Dis. - 2005. - Vol. 45. - P. 1-1537.
  21. Sakurabayashi Kitade S., Aoka Y., Nagashima H. [et al]. Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling inangiotensin II overproducing transgenic mice // Atherosclerosis. - 2009. - Vol. 206(1). - P. 54-60.
  22. Takahashi A., Takase H., Toriyama T. [et al]. Candecartan, an angiotensin II type -1 receptor blocker, reduced cardiovascular events in patients on chronic haemodialysis-a randomized study // Nephrol Dial Transplant. - 2006. - Vol. 21(9). - P. 2507-2512.
  23. Uaesoontrachoon K., Yoo H.J., Tudor E. [et al]. Osteopontin and skeletal muscle myoblasts: Association with muscle regeneration and regulation of myoblast function in vitro // Int. J. Biochem. Cell Biol. - 2008. - Vol. 40(10). - P. 2303-2314.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies